Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma. Issue 13 (10th November 2019)

• Record Type: Journal Article
• Authors: Andraos, Therese Y.; Ayoub, Zeina; Nastoupil, Loretta J; Milgrom, Sarah A.; Pinnix, Chelsea C.; Ng, Sweet Ping; Gunther, Jillian R.; Fowler, Nathan H.; Neelapu, Sattva S.; Samaniego, Felipe; Fayad, Luis E.; Dabaja, Bouthaina S.
• Is Part Of: Leukemia & lymphoma. Volume 60:Issue 13(2019)
• Page Start: 3258
• Page End: 3265
• Publication Date: 2019-11-10
• Subjects: Early-stage follicular lymphoma -- completely resected nodal follicular lymphoma -- radiation therapy -- nodal follicular lymphoma -- excisional biopsy; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2019.1627535
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Patients with early-stage nodal follicular lymphoma (FL) may be rendered free of detectable disease by a diagnostic excisional biopsy. We reviewed the management and outcomes of 48 patients with FL, diagnosed from 2003–2013, treated at a single institution. The primary endpoints were local control (LC) and progression-free survival (PFS). Median age at diagnosis was 54.5 years (range 15–74 years). Forty-seven patients were stage I (97.9%); 15 patients (31.3%) had grade 3 disease. Initial management consisted of observation (12 patients; 25.0%), radiation therapy (RT) alone (12 patients; 25.0%), systemic therapy alone (9 cases; 18.8%), or both (15 patients; 31.3%). Median follow-up was 4.92 years (range 0.5–13.83 years). 4-year PFS and OS were 80.9% and 97.1%, respectively. Patients treated with additional therapy experienced significantly better 4-year LC (100% vs. 81.8%; p = .012) and 4-year PFS (86.7% vs. 63.6%; p = .006). Patients with completely resected limited-stage FL would benefit from therapy beyond excisional biopsy alone.